Federal prosecutors allege that the Fort Worth cardiologist repeatedly approved student-athletes’ cardiovascular studies without conducting a meaningful medical review, turning an electronic “normal” designation into a central element of an $89 million healthcare fraud prosecution.
WASHINGTON, DC — A federal indictment accuses Doctor Jason Finkelstein of repeatedly signing cardiovascular test results as “normal” within seconds of accessing them, despite allegedly failing to perform the careful medical review represented to student-athletes, schools, and health insurers.
The government portrays those rapid approvals as far more than hurried clinical work, alleging that Finkelstein’s electronic signatures helped participating companies present medically unnecessary campus screenings as completed diagnostic services eligible for reimbursement from private and public healthcare benefit programs.
Prosecutors say the most troubling example involved approximately 63 cardiovascular images belonging to one student-athlete, whose records allegedly contained preliminary indications of possible heart enlargement before Finkelstein approved the entire collection as normal approximately eleven seconds after opening it.
The athlete died from sudden cardiac arrest approximately 24 days later while exercising with his basketball team, according to federal authorities, although Finkelstein has pleaded not guilty and remains entitled to contest the medical, factual, and legal conclusions surrounding that tragedy.
Eleven seconds sits at the center of the allegation
The federal indictment against Jason Finkelstein alleges that representatives of the unnamed testing company conducted numerous cardiovascular examinations on the athlete during October 2024, producing an electronic collection containing approximately 63 separate images for physician review.
Some images allegedly carried an unconfirmed interpretation noting possible right atrial hypertrophy and right ventricular hypertrophy, terms describing potential enlargement or thickening affecting the heart’s right-sided chambers and therefore requiring responsible clinical evaluation rather than automatic reassurance.
Prosecutors claim Finkelstein accessed those digital materials on October 26, 2024, and signed all results as normal approximately eleven seconds later, a remarkably compressed interval that the government presents as evidence that no meaningful medical review actually occurred.
Elapsed time alone may not reveal everything a physician knew, reviewed beforehand, delegated, or discussed outside a particular platform, but investigators can combine timestamps with image volumes, user histories, communications, preliminary findings, and billing records to reconstruct an alleged workflow.
That reconstruction will matter because the defense can argue that an electronic access event does not necessarily mark the start of every professional task, while prosecutors can argue that recurring approvals within seconds show a systematic practice rather than an isolated software anomaly.
The word “normal” allegedly carried clinical and financial consequences
A normal result ordinarily communicates reassurance to an athlete, family, trainer, or referring professional, but the government alleges that Finkelstein’s designation also supported claims representing that a qualified physician had interpreted the underlying studies and completed the service being billed.
That dual function makes the approval central to the prosecution, because a diagnostic report can guide patient conduct while also documenting the professional work an insurer expects before reimbursing an electrocardiogram, echocardiogram, or vascular ultrasound examination.
Prosecutors consequently frame the alleged rubber-stamping as a bridge between campus testing and insurance payment, claiming that physician authority converted large volumes of images into apparently completed diagnostic services even when individualized review supposedly never occurred.
The indictment does not suggest that every rapid electronic signature proves fraud, because the criminal case requires evidence of knowing and willful participation, material misrepresentations, and an agreement or execution connected with healthcare payments rather than mere speed or negligence.
However, repeated approval times measured in seconds could become circumstantial evidence of intent if prosecutors establish that the image collections were too extensive for meaningful review and that Finkelstein understood insurers were being told he personally interpreted them.
Electronic records may become the prosecution’s most important witnesses
Unlike disputed memories reconstructed years later, an electronic medical records platform can preserve access times, signature events, user identifiers, image counts, report changes, login locations, and other metadata that can show how test results moved through a clinical and billing system.
Prosecutors may compare Finkelstein’s approval pace across numerous athletes, identify clusters signed during unusually short periods, examine whether abnormal preliminary notations were opened, and determine whether reports changed after insurer questions, patient complaints, or the athlete’s death.
The defense can challenge the reliability and interpretation of those digital records by examining system architecture, clock settings, shared credentials, remote access, preloaded reports, preliminary reviews, batch functions, software limitations, and work completed outside the captured platform.
Authentication will also matter because the government must show that particular activity belongs to Finkelstein, that timestamps mean what investigators claim, and that exported records remain complete enough to support conclusions about individual medical reviews conducted several years earlier.
Combined with emails, text messages, insurer appeals, payment records, and witness testimony, the electronic trail could let jurors decide whether “normal” reflected genuine medical judgment, reckless shortcutting, delegated work, unauthorized account use, or deliberate assistance with fraudulent claims.
The athlete’s death gives the accusation exceptional gravity
The indictment identifies the athlete only through initials, preserving limited privacy while alleging that his October testing contained potential abnormalities that were not communicated before he resumed athletic activity and later suffered fatal cardiac arrest during team exercise.
Federal authorities say Finkelstein knew student athletes could present serious risk, citing a communication in which he allegedly raised concerns about malpractice exposure if a young participant collapsed on a playing field after receiving cardiovascular testing through the program.
That alleged awareness gives prosecutors a potential response to any suggestion that the screening population was uniformly healthy, because the government can argue that Finkelstein himself recognized the possibility of dangerous findings while allegedly maintaining an extremely accelerated approval process.
Yet the emotional force of a young athlete’s death cannot replace proof, and jurors would still need reliable expert testimony addressing what the studies showed, whether appropriate review would have prompted intervention, and how the fatal event occurred.
Responsible reporting must therefore distinguish the government’s clinical narrative from an established causation finding, recognizing that an indictment authorizes prosecution but does not resolve contested cardiology, professional-standard, or criminal-intent questions through adversarial evidence.
Fraud allegations and medical causation remain distinct questions
Prosecutors do not necessarily need to prove that an allegedly false normal designation caused the athlete’s death before establishing healthcare fraud, because the charged offenses focus upon intentional deception used to obtain money connected with healthcare benefits and services.
Conversely, evidence of a tragic outcome does not automatically prove fraudulent billing, since a missed abnormality could arise from negligence, interpretive disagreement, incomplete data, technical failure, or another circumstance falling outside the mental state required for federal criminal liability.
The government will likely present the death as powerful evidence demonstrating why meaningful review mattered, while defense lawyers may seek limits preventing jurors from using grief or hindsight to decide billing intent without separately analyzing every statutory requirement.
The trial judge may consequently face difficult evidentiary questions concerning relevance, unfair prejudice, medical expertise, causation, family testimony, and how prosecutors can describe the athlete’s experience without turning a complex financial prosecution into an uncharged malpractice case.
Prosecutors allege the approvals continued afterward
The indictment says Finkelstein learned about the athlete’s death and the mother’s allegation that his medical clearance contributed to it, yet continued fraudulently signing other student-athletes’ cardiovascular tests as normal without reviewing them afterward.
That assertion may become crucial evidence of knowledge because continued conduct after a specific warning can appear more deliberate than earlier activity performed before anyone identified a potentially catastrophic consequence associated with the accused approval process.
Defense counsel can test when Finkelstein received each communication, what information accompanied it, whether later reviews differed, who controlled the platform, and whether prosecutors have accurately characterized subsequent approvals as unreviewed rather than merely fast.
If the government proves the same seconds-long pattern continued after unmistakable notice, prosecutors may argue the behavior shows conscious disregard for both diagnostic responsibility and billing truthfulness, strengthening their claim that “normal” functioned as an automatic commercial output.
An abdominal ultrasound exchange supports the broader pattern theory
The indictment describes an August 2022 text exchange in which a co-conspirator asked Finkelstein about abdominal aorta ultrasounds routinely conducted and billed through the operation, after which he allegedly responded that he did not read those examinations.
The co-conspirator allegedly questioned why the company performed them, and Finkelstein reportedly agreed with that concern, yet prosecutors say participants continued preparing and submitting claims for abdominal aorta ultrasounds until approximately January 2024.
Those messages could help the government argue that the alleged review failures were understood internally rather than discovered retrospectively, particularly if claims continued representing Finkelstein as a servicing, rendering, referring, or reviewing provider for those tests.
The defense may contend that isolated conversational shorthand lacks necessary context, that another qualified professional handled interpretation, or that billing roles changed afterward, making surrounding records essential before jurors assign criminal meaning to a brief exchange.
A nationwide license portfolio allegedly expanded the workflow
Finkelstein was a board-certified cardiologist licensed in the 48 contiguous states, according to the government, giving the testing companies access to a physician credential that could support claims involving student athletes at campuses nationwide.
Prosecutors allege he served as medical director of a Boca Raton testing company while owning Cardiovascular Testing Services PA and Cardiovascular Healthcare Associates PA, two Texas professional associations through which disputed claims and reimbursements allegedly passed.
That structure placed Finkelstein’s professional authority at several points in the operation, including ordering or referring, reviewing, corporate ownership, and medical direction, making the alleged normal certifications part of a broader system rather than disconnected clinical annotations.
Nationwide licensing is not evidence of wrongdoing by itself, but prosecutors may characterize it as infrastructure that permitted an electronically centralized approval process to support geographically dispersed testing that a narrowly licensed provider could not readily facilitate.
The defense can emphasize that lawful multistate licensure reflects extensive credentialing and does not establish who controlled marketing, sonographer staffing, coding, claim entry, campus relationships, patient questionnaires, or company finances during the charged period.
The alleged testing model began before any result was signed
Prosecutors say marketers obtained campus access by emphasizing fears that apparently healthy athletes could die from sudden cardiac arrest, while promising testing capable of identifying life-threatening conditions without direct cost to participating students at the examination site.
The government further alleges that it offered checks, wire transfers, and gift cards to athletic trainers for student referrals, while participants at certain schools were told the screenings were mandatory before they could continue playing for their teams.
Traveling sonographers allegedly performed substantially the same six-test panel for almost every athlete, including electrocardiograms, echocardiograms, and multiple vascular ultrasound examinations, without any doctor first conducting the individualized clinical assessment insurers generally required for diagnostic coverage.
Against that background, the normal certification allegedly followed a standardized sequence from campus recruitment to reimbursement, allowing prosecutors to present each step as coordinated around volume rather than genuine patient-specific diagnostic need.
Schools, athletes, trainers, and sonographers may provide essential testimony about what they were promised, whether testing appeared optional, how medical histories were gathered, who communicated results, and whether anyone explained that insurance claims would follow.
False diagnoses allegedly made screening claims payable
The government alleges that student questionnaires received false diagnosis codes portraying athletes as having hypertension, elevated blood pressure, or other conditions they did not possess, creating medical-necessity support for tests otherwise treated as noncovered preventive screening.
Claims allegedly identified Finkelstein as the sole ordering or referring provider even though he had not personally examined the athletes to confirm symptoms, medical history, physical findings, or another individualized reason supporting the complete cardiovascular testing panel.
Prosecutors also say place-of-service information sometimes represented that testing occurred at Finkelstein’s Tarrant County office when traveling sonographers had actually performed the examinations on distant college campuses, adding geographical representations to the challenged diagnoses and reviews.
Those layers matter because the alleged falsehoods reinforced one another: diagnosis codes supported necessity, provider identifiers supplied medical authority, service locations described where the work occurred, and electronic normal signatures represented that professional interpretation had been completed.
If prosecutors prove that Finkelstein knowingly participated across several layers, the government can argue that rapid approvals were integral to a deliberately constructed claims process, whereas the defense may characterize responsibility as fragmented among independent employees and organizations.
Reporting distinguished claims submitted from reimbursements received
Houston Chronicle coverage of the alleged cardiovascular testing scheme reported that prosecutors accused Finkelstein of using his two companies to submit approximately $89 million in false claims connected with student athletes across United States campuses.
Health plans allegedly paid approximately $13.1 million of those submissions, a materially smaller amount that should not be confused with the headline figure because attempted billing, insurer loss, forfeiture, restitution, and personal compensation represent different financial measurements.
Prosecutors separately allege Finkelstein received approximately $1.1 million through checks and wire transfers funded by reimbursements obtained through participating entities, while the indictment seeks an approximately $13.15 million forfeiture money judgment if it establishes conviction and tracing.
None of those allegations constitutes an existing debt or forfeiture order, because the government must prove the offenses and satisfy applicable financial remedies before a court can enter restitution, forfeiture, fines, or substitute-asset findings against the defendant.
Four counts convert the alleged workflow into federal charges
Count One charges conspiracy to commit healthcare fraud and wire fraud from approximately January 2019 through December 2025, alleging that Finkelstein knowingly joined others in using materially false representations and interstate communications to obtain healthcare money.
Counts Two through Four charge substantive healthcare fraud tied to three identified claims, including two abdominal aorta ultrasound submissions billed at approximately $150 each and one cardiovascular panel involving the athlete whose later death anchors the government’s safety narrative.
The final identified claim allegedly sought about $975 for an electrocardiogram, echocardiogram, and vascular ultrasound services, showing how relatively modest individual transactions can serve as charged examples in a conspiracy alleging far greater cumulative submissions.
Finkelstein pleaded not guilty, and prosecutors must prove the charged mental state rather than merely establishing that reports were inaccurate, reviews were rushed, coding was disputed, companies earned money, or a patient later experienced a devastating medical outcome.
The defense has multiple pathways for challenging “rubber-stamping”
Defense lawyers may investigate whether preliminary readings occurred before Finkelstein opened the files, whether other clinicians participated, whether image collections contained duplicates, and whether the platform’s recorded interval accurately represents all time devoted to interpretation.
They may also challenge whether Finkelstein personally knew about false diagnoses, place-of-service codes, marketing promises, referral payments, sonographer credentials, appeal documents, or particular claim submissions prepared by employees and outside billing personnel working independently.
Medical experts could disagree about whether the identified images actually established enlargement, whether an unconfirmed automated or preliminary notation required a different conclusion, and whether eleven seconds necessarily proves the absence of informed judgment under the specific circumstances.
Corporate evidence may show how authority was divided among the unnamed Florida company, the two Texas professional associations, co-conspirators, contractors, and billing software providers, allowing the defense to argue that prosecutors have combined distinct responsibilities into one simplified narrative.
Witness credibility will remain equally important because cooperating participants may possess incentives, athletes and trainers may remember events differently, and investigators may have interpreted technical language without the professional or operational context that contemporaneous records could provide.
Patient safety makes this more than a conventional billing case
Many healthcare fraud prosecutions involve services never delivered or equipment never needed, but this indictment alleges that the same professional representation used to secure payment also conveyed a potentially dangerous message: that athletes could safely continue demanding physical competition.
That overlap allows prosecutors to argue that fraudulent certification threatened both insurer funds and human life, while Finkelstein’s defense can insist that a serious clinical allegation must not reduce the government’s obligation to prove knowing financial deception independently.
The case may therefore influence how universities and insurers assess remote cardiovascular screening vendors, particularly when one physician reviews high volumes from many jurisdictions while another organization controls patient acquisition, testing personnel, coding, and claim submission.
Meaningful safeguards could include documented physician examinations, verified sonographer credentials, independent review of abnormal studies, transparent referral arrangements, audit-log retention, rapid escalation procedures, and clear separation between preventive screening and reimbursable diagnostic care.
Those precautions protect patients without presuming Finkelstein’s guilt, because institutions can strengthen oversight whenever allegations expose a plausible vulnerability, even as courts preserve an accused person’s right to fully contest the specific prosecution.
A normal designation demands a reliable communication pathway
Even when a cardiovascular study is interpreted correctly, safety depends upon delivering findings to the appropriate athlete, family, trainer, and treating professional with enough clarity to explain whether follow-up, temporary restriction, or urgent evaluation is recommended.
The indictment suggests that athletes with abnormalities were not told they should stop participating in sports, an allegation that shifts attention from image interpretation alone toward the complete chain connecting test acquisition, physician judgment, communication, and action.
Universities reviewing vendors should therefore ask who owns the medical record, who receives preliminary alerts, who confirms final results, how discrepancies are resolved, and what happens when a physician does not complete review within an established period.
Insurers can similarly examine whether one provider’s approval volumes, access times, campus locations, diagnosis patterns, or repeated six-test combinations differ sharply from comparable practice, using those signals for scrutiny without assuming that an unusual pattern automatically proves fraud.
Presumption of innocence remains the governing standard
An indictment records accusations approved by a grand jury, not factual findings produced after cross-examination, defense evidence, expert disagreement, judicial instructions, and the unanimous determination required for a federal criminal conviction at trial.
Finkelstein therefore remains presumed innocent, and every description of rubber-stamping, false diagnoses, deficient review, kickbacks, concealment, or fraudulent billing must remain attributed to prosecutors unless admitted by the defendant or established through a lawful adjudication.
The defense may argue that the government has transformed disputed clinical performance into criminal intent, while prosecutors will likely contend that the speed, repetition, communications, claims data, and post-warning continuation collectively distinguish an intentional scheme from ordinary error.
No responsible sentence prediction can be made from the indictment alone because any eventual exposure would depend upon the counts resolved, guideline findings, attributed loss, role adjustments, criminal history, restitution issues, judicial discretion, and numerous other individualized factors.
Professional consequences may also proceed separately through licensing boards, hospitals, credentialing organizations, malpractice insurers, employers, and civil litigation, none of which should be confused with the federal jury’s responsibility to decide the charged offenses.
Lawful identity or mobility changes cannot erase the case
The prosecution illustrates a principle addressed in Amicus International’s analysis of legal identity myths, because lawful changes involving a name, residence, citizenship, or documentation do not eliminate an indictment, professional obligation, financial claim, court order, or duty to appear.
Similarly, Amicus International’s explanation of United States extradition procedures describes formal mechanisms governing cross-border surrender, reinforcing that international movement cannot lawfully nullify federal supervision, defeat required appearances, conceal forfeitable property, or bypass enforceable release conditions.
This article examines no public allegation that Finkelstein attempted to flee, conceal his whereabouts, or violate travel restrictions, and these broader principles clarify the continuing force of judicial obligations without implying additional misconduct.
Any defendant released before trial must comply with reporting, travel, employment, contact, and appearance requirements established by the court, and must seek judicial permission before undertaking conduct that could conflict with the controlling order or jeopardize continued release.
The current schedule extends the evidentiary battle into 2027
The Justice Department’s current case information schedules a September 16, 2026 status conference, a March 30, 2027 calendar call, and an April 5, 2027 trial before United States District Judge Aileen Cannon in West Palm Beach.
That timetable gives both sides months to examine electronic audit logs, medical images, questionnaire data, insurer policies, company records, payment flows, messages, campus communications, witness histories, and expert opinions accumulated across an alleged seven-year operation.
Pretrial motions may address medical privacy, discovery volume, expert reliability, electronic authentication, co-conspirator statements, unfair prejudice, billing standards, disputed diagnoses, and the permitted use of evidence concerning the athlete’s death before assembled jurors.
The court may also revisit Finkelstein’s ability to practice medicine while released, but any occupational condition remains a preventive measure governing pretrial conduct rather than proof that the alleged normal certifications were fraudulent.
What investigators must prove about the normal approvals
The government must connect specific electronic signatures to Finkelstein, demonstrate what information was available when each approval occurred, explain why the recorded interval excluded meaningful review, and show how those certifications materially advanced claims submitted to covered healthcare programs.
Prosecutors must further establish knowing participation through evidence that may include recurring timing patterns, incriminating communications, billing representations, corporate authority, financial transfers, continued conduct after warnings, and testimony from people who understood the alleged workflow.
The defense can create reasonable doubt by offering credible alternative explanations for the records, separating Finkelstein from false billing decisions, undermining cooperating witnesses, challenging expert assumptions, or showing that prosecutors misread the technology and medical context.
For jurors, the essential question will not be whether eleven seconds sounds troubling in isolation, but whether the complete evidence proves beyond a reasonable doubt that Finkelstein deliberately used false medical approvals to participate in the charged fraud.
An electronic signature now carries the case’s central meaning
The government’s theory transforms a simple digital word into the case’s defining evidence, alleging that “normal” reassured athletes, concealed potential danger, documented physician work that was never meaningfully performed, and unlocked payment for medically unnecessary testing.
Finkelstein’s defense will have the opportunity to challenge every part of that interpretation, including the accuracy of preliminary findings, significance of access timestamps, allocation of clinical duties, origin of billing data, and connection between approvals and reimbursement.
As the prosecution advances toward trial, the most consequential records may be ordinary platform entries created in seconds, because their meaning could determine whether jurors see a legitimate physician workflow, deficient medical practice, or a deliberate nationwide fraud mechanism.
Until those records, witnesses, and expert opinions are tested in court, Jason Finkelstein remains presumed innocent, while the allegation that he rubber-stamped cardiovascular results as normal remains a serious but unproved claim carrying profound consequences for patients, insurers, universities, and medicine.